Recruiting
Phase 1/2
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
Condition(s) studied
Esophageal Squamous Cell CarcinomaUnresectable Locally Advanced Esophageal Cancer
Investigational drug(s) / intervention(s)
PD-1inhibitor: PD-1 inhibitor, Q3W, until disease progression or unacceptable toxicity or treatment reaches 1 year
nab-paclitaxel + cisplatin: Induction phase: nab-paclitaxel + cisplatin, Q3W × 2 cycles; Concurrent ICRT phase: nab-paclitaxel + cisplatin, QW × 5 cycles
Radiotherapy: Primary tumor and metastatic lymph nodes, DT:45-50Gy/25fx, starting within 4 weeks following the completion of the last induction immunochemotherapy cycle
Study summary
SCR-ESCC-02 is a multicenter, phase I/II clinical study to investigate the safety and efficacy of induction immunochemotherapy followed by concurrent chemoradiotherapy with anti-PD-1 therapy in patients diagnosed with locally advanced, unresectable esophageal cancer.
Eligibility
Inclusion Criteria:
1. Age between 18 and 75 years.
2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
3. Clinical stage meeting the criteria of T1N+M0 or T2-4aN0-3M0 based on the 8th UICC-TNM classification.
4. Ineligibility for surgical resections due to patients' unwillingness for surgery, technically unresectable disease, or being medically unfit for surgery.
5. No prior anti-tumor treatment, including surgery, radiotherapy, chemotherapy, immunotherapy, or targeted therapy.
6. Adequate hematological, pulmonary, cardiac, hepatic, renal, and thyroid function.
7. Willingness to use contraception with an adequate method throughout the study.
8. Documented informed consent.
Exclusion Criteria:
1. History of malignant disease within the 5 years preceding enrollment or presence of other malignant tumors or non-squamous cell carcinoma components.
2. High risk of gastrointestinal bleeding, esophageal fistula, or esophageal perforation as determined by the investigators.
3. Weight loss exceeding 20% within the 90 days prior to the first day of drug administration.
4. Presence of long-standing unhealed wounds or fractures or undergoing major surgical resections within 60 days preceding the first day of drug administration.
5. Presence of any severe or uncontrolled coexisting diseases, including but not limited to:
* Uncontrolled hypertension
* History of interstitial lung disease or non-infectious pneumonia
* Active hepatitis B or C, syphilis, or other active and uncontrolled infections
* Cardiac insufficiency (NYHA≥2)
* Renal dysfunction requiring dialysis
* Active autoimmune disease
* History of acquired or congenital immunodeficiency diseases
6. Occurrence of serious arterial/venous thrombotic events within 6 months prior to the first day of drug administration.
7. History of psychotropic substance abuse or inability to quit, or patients with psychotic disorders.
8. Allergy to study drugs.
9. Patients deemed unsuitable for participation due to severe comorbidities or other reasons determined by the investigators.
Primary outcome measure(s)
- Progression-free survival — Assessed up to 60 months
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first
- Treatment completion rate — 1 year
The Treatment Completion Rate is defined as the percentage of patients who successfully completed concurrent immuno-chemoradiotherapy.
Trial sites (1)
| Facility | City | Region | Status |
|---|
| Shanghai Chest Hospital |
Shanghai |
China |
Recruiting |
More Shanghai Chest Hospital trials in China
Other trials for the same condition
